Also good to consider: This study was funded by the company who created bremelanotide and a pharmaceutical company who licensed it
Equivalent effects have not been established in people
type 2 diabetes (49%), the researchers observed a greater mean reduction in ALT by 32.9 U/L among those with diabetes ( P = .02)
10.1002/mabi.202200097 [DOI] [PubMed] [Google Scholar] Man B., Hu C., Yang G., Xiang J., Yang S., Ma C
10.1016/S0140-6736(09)61307-6 140 PykeC.KnudsenL
Koutros S, Kiemeney LA, Pal Choudhury P, Milne RL, Lopez de Maturana E, Ye Y, Joseph V, Florez-Vargas O, Dyrskjt L, Figueroa J, Dutta D, Giles GG, Hildebrandt MAT , Offit K, Kogevinas M, Weiderpass E, McCullough ML, Freedman ND, Albanes D, Kooperberg C, Cortessis VK, Karagas MR, Johnson A, Schwenn MR, Baris D, Furberg H, Bajorin DF, Cussenot O, Cancel-Tassin G, Benhamou S, Kraft P, Porru S, Carta A, Bishop T, Southey MC, Matullo G, Fletcher T, Kumar R, Taylor JA, Lamy P, Prip F, Kalisz M, Weinstein SJ, Hengstler JG, Selinski S, Harland M, Teo M, Kiltie AE, Tardn A, Serra C, Carrato A, Garca-Closas R, Lloreta J, Schned A, Lenz P, Riboli E, Brennan P, Tjnneland A, Otto T, Ovsiannikov D, Volkert F, Vermeulen SH, Aben KK, Galesloot TE, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Hohensee C, Hunt R, Patel AV, Huang WY, Thorleifsson G, Gago-Dominguez M, Amiano P, Golka K, Stern MC, Consortium U, Yan W, Liu J, Li SA, Katta S, Hutchinson A, Hicks B, Wheeler WA, Purdue MP, McGlynn KA, Kitahara CM, Haiman CA, Greene MH, Rafnar T, Chatterjee N, Chanock SJ, Wu X, Real FX, Silverman DT, Garcia-Closas M, Stefansson K, Prokunina-Olsson L, Malats N, Rothman N
